New approaches in psychiatric drug development

Thalia F. van der Doef, Silvia Zaragoza Domingo, Gabriel E. Jacobs, Wayne C. Drevets, Hugh M. Marston, Pradeep J. Nathan, Maria B. Tome, Carol A. Tamminga, Joop M.A. van Gerven, Martien J.H. Kas

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Numerous novel neuroscience-based drug targets have been identified in recent years. However, it remains unclear how these targets relate to the expression of symptoms in central nervous system (CNS) disorders in general and psychiatric disorders in particular. To discuss this issue, a New Frontiers Meetings of European College of Neuropsychopharmacology (ECNP) was organized to address the challenges in translational neuroscience research that are impeding the effective development of new treatments. The main aim of this meeting was to discuss scientific insights, concepts and methodologies in order to improve drug development for psychiatric disorders. The meeting was designed to bring together stakeholders from academia, pharmaceutical industry, and regulatory agencies. Here we provide a synopsis of the proceedings from the meeting entitled ‘New approaches to psychiatric drug development’. New views on psychiatric drug development were presented to address the challenges and pitfalls as identified by the different stakeholders. The general conclusion of the meeting was that drug discovery could be stimulated by designing new classification and sensitive assessment tools for psychiatric disorders, which bear closer relationships to neuropharmacological and neuroscientific developments. This is in line with the vision of precision psychiatry in which patients are clustered, not merely on symptoms, but primarily on biological phenotypes that represent pathophysiological relevant and ‘drugable’ processes. To achieve these goals, a closer collaboration between all stakeholders in early stages of development is essential to define the research criteria together and to reach consensus on new quantitative biological methodologies and etiology-directed treatments.

Original languageEnglish (US)
Pages (from-to)983-993
Number of pages11
JournalEuropean Neuropsychopharmacology
Volume28
Issue number9
DOIs
StatePublished - Sep 1 2018

Fingerprint

Psychiatry
Pharmaceutical Preparations
Neurosciences
Translational Medical Research
Central Nervous System Diseases
Drug Industry
Drug Discovery
Consensus
Phenotype
Therapeutics
Research

Keywords

  • Drug discovery
  • Neuroimaging
  • Precision medicine
  • Psychiatry
  • Translational research

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Pharmacology (medical)

Cite this

van der Doef, T. F., Domingo, S. Z., Jacobs, G. E., Drevets, W. C., Marston, H. M., Nathan, P. J., ... Kas, M. J. H. (2018). New approaches in psychiatric drug development. European Neuropsychopharmacology, 28(9), 983-993. https://doi.org/10.1016/j.euroneuro.2018.06.006

New approaches in psychiatric drug development. / van der Doef, Thalia F.; Domingo, Silvia Zaragoza; Jacobs, Gabriel E.; Drevets, Wayne C.; Marston, Hugh M.; Nathan, Pradeep J.; Tome, Maria B.; Tamminga, Carol A.; van Gerven, Joop M.A.; Kas, Martien J.H.

In: European Neuropsychopharmacology, Vol. 28, No. 9, 01.09.2018, p. 983-993.

Research output: Contribution to journalReview article

van der Doef, TF, Domingo, SZ, Jacobs, GE, Drevets, WC, Marston, HM, Nathan, PJ, Tome, MB, Tamminga, CA, van Gerven, JMA & Kas, MJH 2018, 'New approaches in psychiatric drug development', European Neuropsychopharmacology, vol. 28, no. 9, pp. 983-993. https://doi.org/10.1016/j.euroneuro.2018.06.006
van der Doef TF, Domingo SZ, Jacobs GE, Drevets WC, Marston HM, Nathan PJ et al. New approaches in psychiatric drug development. European Neuropsychopharmacology. 2018 Sep 1;28(9):983-993. https://doi.org/10.1016/j.euroneuro.2018.06.006
van der Doef, Thalia F. ; Domingo, Silvia Zaragoza ; Jacobs, Gabriel E. ; Drevets, Wayne C. ; Marston, Hugh M. ; Nathan, Pradeep J. ; Tome, Maria B. ; Tamminga, Carol A. ; van Gerven, Joop M.A. ; Kas, Martien J.H. / New approaches in psychiatric drug development. In: European Neuropsychopharmacology. 2018 ; Vol. 28, No. 9. pp. 983-993.
@article{df54accdae8842d284b523cf335da78a,
title = "New approaches in psychiatric drug development",
abstract = "Numerous novel neuroscience-based drug targets have been identified in recent years. However, it remains unclear how these targets relate to the expression of symptoms in central nervous system (CNS) disorders in general and psychiatric disorders in particular. To discuss this issue, a New Frontiers Meetings of European College of Neuropsychopharmacology (ECNP) was organized to address the challenges in translational neuroscience research that are impeding the effective development of new treatments. The main aim of this meeting was to discuss scientific insights, concepts and methodologies in order to improve drug development for psychiatric disorders. The meeting was designed to bring together stakeholders from academia, pharmaceutical industry, and regulatory agencies. Here we provide a synopsis of the proceedings from the meeting entitled ‘New approaches to psychiatric drug development’. New views on psychiatric drug development were presented to address the challenges and pitfalls as identified by the different stakeholders. The general conclusion of the meeting was that drug discovery could be stimulated by designing new classification and sensitive assessment tools for psychiatric disorders, which bear closer relationships to neuropharmacological and neuroscientific developments. This is in line with the vision of precision psychiatry in which patients are clustered, not merely on symptoms, but primarily on biological phenotypes that represent pathophysiological relevant and ‘drugable’ processes. To achieve these goals, a closer collaboration between all stakeholders in early stages of development is essential to define the research criteria together and to reach consensus on new quantitative biological methodologies and etiology-directed treatments.",
keywords = "Drug discovery, Neuroimaging, Precision medicine, Psychiatry, Translational research",
author = "{van der Doef}, {Thalia F.} and Domingo, {Silvia Zaragoza} and Jacobs, {Gabriel E.} and Drevets, {Wayne C.} and Marston, {Hugh M.} and Nathan, {Pradeep J.} and Tome, {Maria B.} and Tamminga, {Carol A.} and {van Gerven}, {Joop M.A.} and Kas, {Martien J.H.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.euroneuro.2018.06.006",
language = "English (US)",
volume = "28",
pages = "983--993",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
number = "9",

}

TY - JOUR

T1 - New approaches in psychiatric drug development

AU - van der Doef, Thalia F.

AU - Domingo, Silvia Zaragoza

AU - Jacobs, Gabriel E.

AU - Drevets, Wayne C.

AU - Marston, Hugh M.

AU - Nathan, Pradeep J.

AU - Tome, Maria B.

AU - Tamminga, Carol A.

AU - van Gerven, Joop M.A.

AU - Kas, Martien J.H.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Numerous novel neuroscience-based drug targets have been identified in recent years. However, it remains unclear how these targets relate to the expression of symptoms in central nervous system (CNS) disorders in general and psychiatric disorders in particular. To discuss this issue, a New Frontiers Meetings of European College of Neuropsychopharmacology (ECNP) was organized to address the challenges in translational neuroscience research that are impeding the effective development of new treatments. The main aim of this meeting was to discuss scientific insights, concepts and methodologies in order to improve drug development for psychiatric disorders. The meeting was designed to bring together stakeholders from academia, pharmaceutical industry, and regulatory agencies. Here we provide a synopsis of the proceedings from the meeting entitled ‘New approaches to psychiatric drug development’. New views on psychiatric drug development were presented to address the challenges and pitfalls as identified by the different stakeholders. The general conclusion of the meeting was that drug discovery could be stimulated by designing new classification and sensitive assessment tools for psychiatric disorders, which bear closer relationships to neuropharmacological and neuroscientific developments. This is in line with the vision of precision psychiatry in which patients are clustered, not merely on symptoms, but primarily on biological phenotypes that represent pathophysiological relevant and ‘drugable’ processes. To achieve these goals, a closer collaboration between all stakeholders in early stages of development is essential to define the research criteria together and to reach consensus on new quantitative biological methodologies and etiology-directed treatments.

AB - Numerous novel neuroscience-based drug targets have been identified in recent years. However, it remains unclear how these targets relate to the expression of symptoms in central nervous system (CNS) disorders in general and psychiatric disorders in particular. To discuss this issue, a New Frontiers Meetings of European College of Neuropsychopharmacology (ECNP) was organized to address the challenges in translational neuroscience research that are impeding the effective development of new treatments. The main aim of this meeting was to discuss scientific insights, concepts and methodologies in order to improve drug development for psychiatric disorders. The meeting was designed to bring together stakeholders from academia, pharmaceutical industry, and regulatory agencies. Here we provide a synopsis of the proceedings from the meeting entitled ‘New approaches to psychiatric drug development’. New views on psychiatric drug development were presented to address the challenges and pitfalls as identified by the different stakeholders. The general conclusion of the meeting was that drug discovery could be stimulated by designing new classification and sensitive assessment tools for psychiatric disorders, which bear closer relationships to neuropharmacological and neuroscientific developments. This is in line with the vision of precision psychiatry in which patients are clustered, not merely on symptoms, but primarily on biological phenotypes that represent pathophysiological relevant and ‘drugable’ processes. To achieve these goals, a closer collaboration between all stakeholders in early stages of development is essential to define the research criteria together and to reach consensus on new quantitative biological methodologies and etiology-directed treatments.

KW - Drug discovery

KW - Neuroimaging

KW - Precision medicine

KW - Psychiatry

KW - Translational research

UR - http://www.scopus.com/inward/record.url?scp=85050334255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050334255&partnerID=8YFLogxK

U2 - 10.1016/j.euroneuro.2018.06.006

DO - 10.1016/j.euroneuro.2018.06.006

M3 - Review article

C2 - 30056086

AN - SCOPUS:85050334255

VL - 28

SP - 983

EP - 993

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 9

ER -